JP4993979B2 - Capillary circulatory improving agent containing Raffma extract component - Google Patents

Description

  The present invention belongs to the technical field of a capillary circulation improving agent containing a rough extract component that improves the density and blood flow velocity of capillaries.

Conventionally, continuous and dynamic measurement of capillary diameter, blood velocity, flow rate, blood vessel density, etc. is performed by magnifying and observing the movement of capillary blood flow in the nail epithelium of the fingertip, which is a microvessel. In order to observe the state of the capillary, the present inventors have already provided as Patent No. 3025671 (Patent Document 1), and the blood circulation is increased when the number of microvessels is larger. It is known that the better the blood flow rate is, the better the blood flow rate is.
In order to improve the density and blood flow velocity of the capillaries, it is effective for the present inventors to use ganoderma carbide as a food additive or food additive as Patent No. 3545290 (Patent Document 2). I have found that.
By the way, traditionally, Rahuma (scientific name: Apocynum venetum) is a perennial herbaceous herbaceous plant that is widely distributed in China (herbaceous is what is commonly called "grass"). Rafuma is named “Rafu hemp” because it is rich in fiber and used like hemp and its origin is “Lopnor” in Xinjiang, China. Since Raffma is a plant, its contents and active ingredients are quite different, which is easily affected by soil, climate change, solar radiation time, rainfall, etc.
In China, Rafu hemp leaves have been used as a substitute for tea leaves since ancient times, and the rafuma tea has also been used as a folk medicine for antipyretic and so on. In addition, several Chinese research institutes are conducting medical and pharmaceutical research on Rahuma leaves, which are used as folk medicines, and as a result, they are reported to be effective for hypertension, heart failure, bronchitis, edema, etc. Has been. On the other hand, in Japan, Rama tea is marketed as, for example, trade name: Oolong tea, and is attracting attention as a tea having various effects.
Also, Raffa tea with roasted Raffa leaves to enhance cholesterol-lowering effect is disclosed in Japanese Patent No. 3517318 (Patent Document 3), and Raffa extract is used for the prevention and treatment of intestinal infections such as enterohemorrhagic Escherichia coli. This is disclosed in Japanese Patent Application Laid-Open No. 10-167978 (Patent Document 4), and isoflavcitrin, which is a flavonoid compound, is extracted from rafuma leaves and used as an antidepressant for depression, Japanese Patent Application Laid-Open No. 2002-201139 (Patent Document 5). Is disclosed.
Regarding the effect of Luffa leaves, “Biopharmaceutical” describes sedation; headache, dizziness; hypertension; diuresis; liver function assistance, etc., but it is not known to have an effect of improving capillary circulation.

Japanese Patent No. 3025671 Japanese Patent No. 3545290 Japanese Patent No. 3517318 JP-A-10-167978 JP 2002-201139 A

  An object of the present invention is to provide an agent for improving capillary circulation that is safe for the human body and improves blood circulation such as blood pressure, capillary density, blood flow velocity, and the like, using an extracted component of Rahma leaves.

In order to solve the above-mentioned problems, the invention of claim 1 is characterized in that isoquercitrin is 6 wt% or more, quercetin is 0.3 wt% or more of Raffa leaf extract having a high content of 10 to 25 wt%, and leaf extract 8-12% ginkgo, a capillary circulation improving agent containing a Lafuma extracted components sweet grass extract which is characterized in that a mixture of a 8-12% by weight.

According to the present invention, because of the use of extracted components La fumarate leaves are safe to the human body, there are advantageous effects of lowering blood pressure with respect to hypertensive patients, increasing the density of the capillaries is microcirculatory blood vessels, capillary There are improving effects such as increasing the blood flow velocity in the blood vessel, increasing the blood flow volume, and expanding the blood vessel diameter of the capillary blood vessel.

Feature of the present invention, the utility of Lafuma leaves, sedation; headache, dizziness; hypertension; diuretic; the like liver function aid is known, main ingredient Lafuma leaves equi scan with a high content of iso Beautique Le citrine and quercetin As a result of conducting animal experiments and clinical experiments on the product of the present invention, it has been found that, as well as the above-mentioned effects, a new effect of improving capillary circulation is also found.
The present invention Lafuma leaf extract with a high content of the iso Beautique Le citrine and quercetin, licorice extract, and a main agent of the three components of the Ginkgo biloba extract, in among them those the Lafuma leaves equi scan the most important components, other The main ingredient licorice extract is used for palpitations, hysteria, throat inflammation, cough, poisoning (food, drugs) treatment, abdominal pain, liver protection, adrenal cortex function decline, skin inflammation, drug harmony, etc. It is used for sequelae of vascular disorders, dementia assistive treatment, bronchitis, sedation, etc., but the present invention is a capillary that has not been discovered so far by mixing the above three of Luffa leaf extract, Ginkgo biloba extract, and licorice extract. I came up with the effect on blood vessels.
In the following, the present invention will be described with reference to examples. In order to confirm the effect, an animal experiment with rats and a clinical experiment with human subjects targeting hypertensive patients were performed.

[1: Experimental materials and experimental methods in animal (rat) experiments]
For this experiment, in order to confirm the effects of Example 1 and Example 1 of the present invention described below, Comparative Examples 1 to 3 were created and experimented.
The compositions of Example 1 and Comparative Examples 1 to 3 are as follows.

The component blending ratio of Example 1 is shown in [Table 1].
(Table 1) Component mixing ratio of Example 1 (ratio is% by weight)
Raffma extract (main agent) * 14% (containing 35 mg of Raffa extract)
Licorice extract (main agent) 10%
Ginkgo biloba extract (main agent) 10%
Beer yeast 10%
Dextrin 44%
Crystalline cellulose 10%
Sucrose fatty acid ester 2%
Total (tablet) 250mg 100%

The luffa extract used in Example 1 was obtained by using a luffa leaf specially produced in Xinjiang, China, and extracting the extract by an ultrasonic extraction method. As a specific active ingredient, only one kind of isoquercitrin has been confirmed in the commercially available rafma extract so far. Among the rafma extracts used in this example, an isoquer is used. Two substances, 6% by weight of citrin and 0.3% by weight of quercetin, were detected in high content. This isoquercitrin and quercetin, particularly quercetin, is said to have an action of expanding arteriole smooth muscle.
It was not possible to confirm the content of quercetin in the active ingredient of the commercially available rafma extract of Comparative Example 2 described later.
Also, beer yeast other than the main ingredient is mixed with it because it is good for digestive system and rich in minerals. For the other three ingredients, select ingredients that do not interfere with the main ingredient as excipients to form tablets. It is used.

(Comparative Example 1)
(Table 2) Composition of Comparative Example 1 (Rahma extract only) (ratio is% by weight)
Raffa extract 20% (Raffma extract 50mg included)
Beer yeast 10%
Dextrin 58%
Crystalline cellulose 10%
Sucrose fatty acid ester 2%
Total (tablet) 250mg 100%

(Comparative Example 2)
(Table 3) Ingredients of Comparative Example 2 (commercially available rafma extract: quercetin cannot be confirmed) (ratio by weight)
Commercially available rafma extract (main ingredient) * 20% (containing 50 mg of commercially available rafma extract)
Licorice extract (main agent) 10%
Ginkgo biloba extract (main agent) 10%
Beer yeast 10%
Dextrin 38%
Crystalline cellulose 10%
Sucrose fatty acid ester 2%
Total (tablet) 250mg 100%

(Comparative Example 3)
(Table 4) Composition ratio of Comparative Example 3 (placebo: untreated control group) Saline 100%

  Animal experiments were carried out on two cases in which the input amount of Example 1 was changed and on Comparative Examples 1 to 3. Details will be described below.

(1) Test animal
Wistar rat, with acupuncture, weight around 200g.

(2) Target reagent 1) Tablet of Example 1
2) Comparative Example 1 (Rahma extract only: Wakayama Research Institute)
3) Comparative Example 2 Commercial Raffma Extract (commercially available product)
4) Comparative Example 3 Saline alone (control group)
The above reagents 1) to 3) are dissolved by polishing with physiological saline, vibrated in a warm water bath at 80 ° C. for 4 hours, frozen at −30 ° C., and then thawed in a water bath at 37 ° C. This operation is repeated three times, followed by centrifugation (1600 rpm) for 10 minutes, and the filtered solution is diluted to 0.2 g / ml with physiological saline and stored in the refrigerator.

(3) Experimental instruments The instruments used in the experiment were the mesenteric transfusion device, RM-6300 type physiological recording machine (NIHON KODEN), TIAC-I type constant velocity intravenous injection machine (HARVARD APPARATUS), ZL301 type microcirculation measurement Machine.

(4) Experimental method The state of mesenteric microcirculation disorder is observed. The drug treatment is as follows.
First, the rats are fasted only by supplying water from the 2nd day before the experiment, and 5 ml / kg of 20% urethane is anesthetized by intraperitoneal injection of the rats. The common carotid artery is then separated, blood pressure is recorded, the femoral vein is separated, and the prepared saline is infused from the femoral vein at a constant rate.
Open the abdominal cavity about 2 cm, spread the ileum of the ileocecum on the perfusion table, and perfuse 37 ° constant temperature Ringer's solution. Under a microscope, the visual field with all the arterioles, capillaries, and venules is searched, a video of normal microcirculation is recorded, and 8% / kg of 10% polymer dextran is injected intravenously. Constant-speed intravenous injection.
Ten minutes after injection, disturbances of microcirculation appear. That is, the feature of this animal model is that after 10 minutes of intravenous injection of high molecular weight dextran and thrombin, typical circulatory disturbances appear in the mesentery, the blood flow rate and blood perfusion rate decrease, Blood pressure also decreases. Blood pressure in untreated animals gradually recovers, but microcirculatory disturbances persist for over an hour.

Here, the experiment is started. As Example 1-1, 140 mg / kg with respect to 1 kg body weight of the rat as Example 1-1, 70 mg / kg as in Example 1-2, and 100 mg of Comparative Example 1 containing the present Luma. In the same manner, 100 mg / kg of the one containing the commercially available Ruffa of Comparative Example 2 is intravenously injected. The control group of Comparative Example 3 is given the same amount of physiological saline. This result will be described in the following (5).
The groupings of the test rats were as follows: Example 1-1 (140 mg / kg) n = 7, Example 1-2 (70 mg / kg) n = 8, Comparative Example 1 (the Raffma 100 mg / kg) n = 8 8 and Comparative Example 2 (commercially available Raffa 100 mg / g) were n = 8, and Comparative Example 3 (untreated saline: control group) was n = 7.
The polymer dextran is a product of Shanghai Glucose Manufacturing Co., and thrombin is a product of Sigma. When used, it is diluted to 2 μ / ml with physiological saline. Urethane is a product of Shanghai Chemical Reagent Purchasing and Supply Factory, and Ringer's solution is dispensed when used at pH 7.4.

(5) Experimental results In the previous section (4), after the microcirculatory blood vessel disorder appeared, the above-described Example 1-1, Example 1-2, Comparative Example 1, Comparative Example 2, and Comparative Example 3 were administered. The blood flow state at 5, 10, 20, 30, 45, and 60 minutes was observed and recorded, and the density, diameter, blood flow velocity, and the like of the microvessels were measured.
[Change rate of blood flow velocity in microcirculatory vessels]
The graph of FIG. 1 displays the rate of change in blood flow velocity in the microcirculating blood vessel. The rate of blood flow is measured at each time zone after medication, and the rate of change is calculated by comparison with that before medication. By administering Example 1-1 (140 mg / kg), the blood flow rate was remarkably increased, and the duration of action was 1 hour or longer. Example 1-2 (70 mg / kg) and Comparative Example 1 The blood flow velocity of (Raffma 100 mg / kg in this case) and Comparative Example 2 (commercially available Raffa 100 mg / kg) increased, but the effect became weak after 30 minutes. Nevertheless, the effect of Example 1-2 (70 mg / kg) is superior to Comparative Examples 1 and 2 after 1 hour. Further, no change in blood flow velocity appeared in the test rats of Comparative Example 3 containing only physiological saline.
As a result, even in the case of different doses as in Examples 1-1 and 1-2, the present Example 1 shows the blood flow velocity in the microcirculatory blood vessels such as capillaries as compared with the comparative example of Ruffa alone or commercially available Raffa. It turns out that it is effective for improvement.

[Change rate of blood flow in microcirculatory vessels]
The graph of FIG. 2 displays the rate of change in blood flow in the microcirculatory blood vessel, but measures the blood flow velocity of the venule before and after administration of the reagent and the inner diameter of the blood vessel, and calculates the amount of blood flow by a calculation formula. The relative value of the microcirculatory blood flow was obtained by dividing by the mean blood pressure at that time.
The blood flow rate of the group to which Example 1-1 (140 mg / kg) was administered was markedly increased compared to Comparative Example 3 (control group). The blood flow rate of the group administered with Example 1-2 (70 mg / kg) was increased compared to Comparative Example 3 (control group), but smaller than that of Example 1-1 (140 mg / kg). Although the blood flow rate is also changed in the group of 1 (this case, Raffma 100 mg / kg), the duration is shorter than that of Example 1-1 and Example 1-2. Was weaker and the duration was even shorter.
From this result, even in the case of different doses as in Examples 1-1 and 1-2, this Example 1 improves the blood flow rate in the microcirculatory blood vessels compared with the comparative example of Ruffa alone or commercially available Raffa. It turns out that it is effective.

[Change rate of the diameter of microcirculatory vessels]
The graph of FIG. 3 displays the change rate of the caliber in the microcirculating blood vessel. The caliber of the microvascular orifice before and after administration is different from that before administration in the control group of Comparative Example 3. While the average was reduced by 12%, Example 1-2 (70 mg / kg) was 10.5%, and the diameter of the microvessel of Example 1-1 (140 mg / kg) was increased by 15% compared to before administration. Comparative Example 1 (Raffma 100 mg / kg) was improved over the Comparative Example 2 (commercial Raffa 100 mg / kg) group and the Comparative Example 3 control group, but weaker than the Example 1-1 and Example 1-2 groups. It was.
From this result, the diameter of the microcirculating blood vessel in Example 1 is larger than that of the comparative example of Ruffa alone or commercially available Raffa even if the dose is different as in Examples 1-1 and 1-2.

  As described above, in the experiments on rats, those of Example 1 (1-1, 1-2) are all the blood flow rate change rate, blood flow rate change rate, and caliber change rate of the microcirculation blood vessels. It can be seen that there is an effect superior to that of the comparative example.

[2: Effects on blood pressure and microcirculatory blood vessels in hypertensive patients]
Next, experiments on blood pressure and microcirculatory blood vessels of hypertensive patients were conducted. In addition to Example 1 of the present invention described above, the reagent was changed to Example 2 of the present invention, in which the composition of Rahma extract was changed. As Example 3 and Comparative Example 4, a placebo containing no rough extract was prepared and tested. The compositions of Example 2, Example 3, and Comparative Example 4 are as follows.

(Table 5) Component mixing ratio of Example 2 (ratio is% by weight)
Raffa extract (main ingredient) * 10% (Roughma extract 25mg)
Licorice extract (main agent) 12%
Ginkgo biloba extract (main ingredient) 12%
Beer yeast 10%
Dextrin 44%
Crystalline cellulose 10%
Sucrose fatty acid ester 2%
Total (tablet) 250mg 100%

(Table 6) Component formulation of Example 3 (ratio is% by weight)
Raffma extract (main ingredient) * 25% (Roughma extract 62.5mg included)
Licorice extract (main agent) 8%
Ginkgo biloba extract (main ingredient) 8%
Beer yeast 10%
Dextrin 37%
Crystalline cellulose 10%
Sucrose fatty acid ester 2%
Total (tablet) 250mg 100%

(Comparative Example 4)
(Table 7) Composition of Comparative Example 4 (ratio is% by weight)
Beer yeast 10%
Dextrin 68%
20% crystalline cellulose
Sucrose fatty acid ester 2%
Total (tablet) 250mg 100%

Experiments were conducted on Examples 1 to 3 and Comparative Example 4 described above. The details will be described below.
(1) Subjects Diagnosed for hypertension according to “WHO / ISH (World Health Organization / International Hypertension Society) 1999 Guidelines for Hypertension Management”, collected 120 patients, and randomly treated group 1, treatment group 2, treatment group Divided into 3 and untreated control group.
Treatment group 1 receives one tablet of the reagent of Example 1 (containing 35 mg of Raffa extract) / times 3 times / day.
In the treatment group 2, one tablet of the reagent of Example 2 (containing 25 mg of Raffa extract) / times is administered 3 times / day.
In the treatment group 3, one tablet of the reagent of Example 3 (containing Roughma extract 62.5 mg / time) is administered 3 times / day.
The placebo of Comparative Example 4 is administered to the control group.
The patients in Group 4 had already taken a hypotensive agent continuously for more than 1 month before the experiment, and no significant blood pressure lowering effect was observed. Continue to take the same medicine after the experiment begins. Also, as exclusion criteria, under 18 years old or over 70 years old, patients with secondary hypertension, pregnant or lactating women, patients with serious diseases in liver, kidneys, hematopoietic system, psychosis, can not take 3 consecutive months People were excluded.
[Table 8] in FIG. 4 shows the general situation of the four groups of patients (n in Tables 8 to 10 is the number of patients), and it was confirmed that there was no significant difference.

(2) Experimental method The experimental period is 12 weeks, and the antihypertensive agent administered to Group 4 is one of calcium antagonist (Amlodipine Besylate), converting enzyme blocker (Benazepril), and β receptor blocker (Betaloc). Or several types. The control group was only an antihypertensive agent, the treatment group 1 was once a tablet of Example 1 (35 mg) 3 times / day, the treatment group 2 was once a tablet of Example 2 (25 mg) 3 times / day. In the treatment group 3, take 1 tablet of Example 3 (62.5 mg) at a time, 3 times / day in combination.
Then, subjective symptoms were confirmed, blood pressure was measured, and microcirculation was examined (average density of capillaries, inlet diameter, outlet diameter, blood flow velocity, etc. were measured and analyzed) and the like.
Test items are changes in blood pressure before and after the experiment; changes in the microcirculation state; subjective symptoms; signs. Judgment criteria are “Guidelines for clinical guidance on hypertension treatment of new drugs (herbal medicines), edited by the Department of Pharmacy, Ministry of Health, China. ”And expressed as prominent, valid, or invalid. Statistical processing was performed by t-test or chi-square test.

(3) Experimental result [Table 9] of Drawing 5 shows change of blood pressure of four groups before and after an experiment. As is clear from this [Table 9], the blood pressure in the control group after administration of placebo in Comparative Example 4 hardly changed, whereas in Examples 1 to 3, the blood pressure was decreased. I understand.
In addition, changes in the capillary state of the four groups before and after the administration of the reagent, in particular, changes in the density of looped capillaries by capillary observation of the nail epithelium of the fingertip (Patent No. 3025671), inlet diameter, outlet diameter, and flow velocity of the blood vessels Is shown in [Table 10] of FIG. As is clear from this [Table 10], the loop density in the control group after administration of the placebo in Comparative Example 4 hardly changed, whereas in Examples 1 to 3, the loop density increased, In each example, the degree of spread of the inlet diameter and the outlet diameter is larger than that of Comparative Example 4.

Furthermore, regarding changes in subjective symptoms / signs, subjective symptoms / signs: dizziness, headache, headweight, chest pain, arrhythmia, insomnia, weakness, etc. In 2 cases (6.5%), 18 cases (58.1%) and 11 cases (35.4%), the total effective rate was 64.5%, whereas “the treatment group of Example 1” 1 ”marked, effective, invalid rate is 3 cases (9.7%), 25 cases (80.6%), 3 cases (9.7%), the total effective rate is 90.3%, The remarkable, effective and ineffective ratios of “treatment group 2 of Example 2” were 2 cases (6.7%), 21 cases (70%), 7 cases ineffective (23.3%), and the total effective rate was 76. The percentage of remarkable, effective and ineffectiveness of “treatment group 3 of Example 3” was 2 cases (7%), 23 cases effective (82.1%), 5 cases ineffective (17.9%) ) The total effective rate is 89.1%.
Thus, the total effective rate of treatment group 1 of Example 1 and treatment group 3 of Example 3 of the placebo compared to the control group of Comparative Example 4 is very high and is significantly higher than that of the control group of Comparative Example 4. There was a difference. The treatment group 2 of Example 2 was also clearly different from the control group of Comparative Example 4, but the total effective rate was lower than the treatment groups 1 and 3.
There is a significant difference between these four groups (p <0.05, treatment groups 1 and 3 and treatment group 2, treatment group 2 and control group comparison; p <0.01, treatment group 1, 3 and comparison group comparison) . Treatment groups 1 and 3 have the same level of efficacy. There was no significant difference between treatment groups 1 and 3.

As described above, it was confirmed that each of the examples containing the Raffa extract of the present invention is a capillary circulation improving agent that lowers blood pressure and improves blood circulation such as capillary density and blood flow velocity.
That is, according to the results of the rat experiment and the hypertension clinical experiment, Example 1 has an effect of improving microcirculation. In animal experiments, Example 1 shows an improvement effect on capillary blood flow velocity, blood flow volume, and blood vessel caliber in the microcirculation disorder in the blood highly-aggregated state by the reagent, which is more remarkable than the Ruffa extract single product of the comparative example. In addition, it was confirmed that the effect of improving the microcirculation of the Raffa extract itself was superior to that of the commercially available Raffa extract.
In clinical experiments with hypertensive patients, antihypertensive drugs were administered for one month or longer, and patients with poor blood pressure control were given 1 tablet each of Example 1 (35 mg) and Example 2 (62.5 mg) 3 times / day, When administered continuously for 12 weeks, the patient's blood pressure and microcirculation were clearly improved from the placebo control group of Comparative Example 4, and there were significant differences. A group in which one tablet of Example 2 (25 mg) was administered 3 times / day for 12 weeks continuously showed a decrease in blood pressure and an improvement in microcirculation, but it was weaker than treatment group 1. There is no significant difference between treatment group 3 and treatment group 1, and it can be seen that the strength of action of Raffa extract is related to the appropriate concentration.
However, the present Luma extract is less effective at 10% by weight or less of Example 2, and the effect is not significantly improved even at 25% by weight of Example 3 of 14% by weight (Example 1) or more. From the viewpoint of physiological safety, it is optimally 14% by weight.
Ginkgo biloba extract is also less effective at 8% by weight or less, and 12% by weight or more is not preferable for the same reason, and is optimally 10% by weight of Example 1. Similarly, licorice extract is less effective at 8% by weight or less, preferably 12% by weight or more for the same reason, and optimally 10% by weight of Example 1.
That is, 10 to 25% by weight of a high-content raquema extract of isoquercitrin and quercetin, 8 to 12% by weight of the ginkgo biloba extract, and 8 to 12% by weight of the licorice extract may be mixed. More preferably, it is 14 to 25% by weight.

The present inventors have published a study on the effect of lowering blood pressure due to the increase in the number of capillaries by the administration of crude drugs and the expansion of the entrance and exit, but the reduction in blood pressure in the examples of the present invention is also the number of capillaries This is probably due to an increase in the number of entrances and exits.
In addition, the rough extract used in this example differs from commercially available rough product from other companies in the following three points, which are considered to be involved in the operation of the example of the present invention.
(1) The Raffa extract used in the present invention is a product obtained by extracting the extract by the ultrasonic extraction method using a Raffa leaf specially produced in Xinjiang, China. As a unique active ingredient, only one kind of isoquercitrin has been confirmed so far by other companies, but our extract contains 6% by weight of isoquercitrin, Two substances, 0.3% by weight of quercetin, were detected in high content. Isoquercitrin and quercetin, especially quercetin, have a dilating action on arteriole smooth muscle. The same was confirmed in this experiment. In addition, confirmation of the active ingredient of the Lafuma leaf extract, China 2005 edition medicine Source: is specified According to the National Pharmacopeia seal ed. Apocynum Asakabutomoto (isoquercitrin) to Luo cloth Asaotsumoto ^{(quercetin)].}
(2) In addition to isoquercitrin and quercetin, examples of the present invention include licorice extract active ingredient glycyrrhizin and ginkgo biloba extract active ingredient terpene lactone (ginkgolide A, B, C, J And bilobalide), quercetin, and the like, and it seems that the synergistic effect of quercetin is particularly apparent.
(3) It was confirmed that the effect of the embodiment of the present invention was an improvement effect on microcirculating blood vessels (increase in the number of capillaries, expansion of the inlet and outlet).

From the above animal experiments and clinical experiments, Raffa mixed with Raffa leaf extract, Ginkgo biloba leaf extract and licorice extract containing 6% by weight or more of isoquercitrin and 0.3% by weight or more of quercetin. The capillary circulation improving agent of Examples 1 to 3 containing an extract component is safe for the human body because it uses an extract component of Rahma leaves, and has the effect of lowering blood pressure for hypertensive patients, It has been confirmed that there are improving effects such as increasing the density of capillaries, which are microcirculatory vessels, increasing the blood flow velocity in capillaries, increasing the blood flow volume, and expanding the diameter of capillaries.
The composition ratio is preferably 10 to 25% by weight of the rafuma leaf extract high in the present case of isoquercitrin and quercetin, 8 to 12% by weight of the ginkgo biloba extract, and 8 to 12% by weight of the licorice extract. As in Example 1, the optimal value for the improvement of capillary circulation was a mixture of approximately 14% by weight of the luffa leaf extract containing the present isoquercitrin and quercetin, and approximately 10% by weight of the ginkgo biloba extract. %, Licorice extract is approximately 10% by weight.
It should be noted that the present invention is not limited to the above-described embodiment as long as it does not impair the characteristics of the present invention, and the embodiment of the present invention is based on three main components (ruffa, licorice, ginkgo biloba extract). Calcium (pearl powder, oyster shells, animal bones, etc.), black baked (fungi, bamboo, trees, etc.), gabba, gold needle vegetables, potatoes, lily roots, lotus seeds, kokushi, soy sauce Of course, it is possible to mix night-going wisteria, Keiso, Gokasan, Bodaiju, Toki, Tochu, peony, and cocoon.

The figure of the graph of the blood-flow rate change rate of the microcirculation blood vessel of the Example and comparative example of this invention The figure of the graph of the blood flow rate change rate of the microcirculation blood vessel of the Example of this invention, and a comparative example The figure of the graph of the change rate of the diameter of the microcirculation blood vessel of the Example of this invention and a comparative example [Table 8] Diagram of Comparison of General Conditions of Group 4 Patients of Example and Comparative Example of the Present Invention [Table 9] diagram of comparison of blood pressure change before and after experiment of Example and Comparative Example of the present invention FIG. 10 is a table of [Table 10] showing changes in capillary state before and after the four-group experiment of an example of the present invention and a comparative example.

Claims (1)

Iso Beautique Le citrine 6 wt% or more, and 10 to 25% by weight of Lafuma leaf extract with a high content of more than 0.3% by weight quercetin, and 8-12 wt% ginkgo leaf extract, sweet grass extract A capillary circulation improving agent containing a Ruffa extract component, characterized by mixing 8 to 12% by weight.

Images